Core binding factor acute myeloid leukemia (CBF-AML) includes AML cases harboring RUNX1::RUNX1T1 or CBFβ::MYH11 fusion genes, which are classified as a favorable-risk group [1, 2]. This evidence concerns the gene CEBPZ and acute myeloid leukemia.